Dr
European Commission, Joint Research Centre, Directorate for Nuclear Safety and Security
Author in the following contributions
- Therapeutic efficacy of 225Ac-containing polymersomes
- The therapeutic potential of anti-HER2 2Rs15d nanobody labeled with 225Ac – an in vitro and in vivo evaluation
- Combining Bismuth-213 with Nanobodies: finding the perfect match for Targeted Alpha Therapy
- Improved tumor control and absence of late neurotoxicity using alpha (213Bi) as compared to beta (90Y) labelled-DOTA-Substance P for the treatment of low grade gliomas
- The response of human papillomavirus associated head and neck squamous cell carcinoma cell lines on standard therapy and treatment with an experimental alpha-particle emitter immunoconjugate targeting EGFR (Bi-213-Cetuximab)
- 225Ac-labeled girentuximab for targeted alpha therapy of CAIX-expressing renal cell cancer xenografts.
- Pharmacokinetic variability of in vivo generated 213Bi and vector labeled 225Ac in murine cancer models
- 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer
- Alpha-particle nanotherapeutics against recurrent, chemoresistant Triple Negative Breast Cancer
- Safety and therapeutic efficacy of 225Ac-DOTA-Substance P for therapy of brain tumors
- Safety and efficacy of Ac-225-PSMA-617 in mCRPC after failure of Lu-177-PSMA